{
  "id": 20646457,
  "title": "IceCure (ICCM) Q3 2026 Earnings Call Transcript",
  "url": "https://urgent.news/2026/11/18/icecure-iccm-q3-2026-earnings-call-transcript",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T19:43:58.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/call-transcripts/2026/11/18/icecure-iccm-q3-2026-earnings-call-transcript/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "On the IceCure earnings call for Q3 2026, the company reported an 83% increase in U.S. sales as it expanded its commercial reach to 21 states. Total revenue for the period grew 26%, driven by increased physician adoption of the ProSense cryoablation system. Management emphasized the progress made in advancing the ChoICE post-marketing study, securing regulatory approval in China, and establishing a distribution agreement in the Netherlands. Financial results showed an increase in operating loss to $12.9 million, attributed to investments in U.S. sales and ongoing clinical development activities. The company maintains $8.2 million in cash to support its growth strategy. The operator reminded participants that the call contained forward-looking statements subject to risks and uncertainties described in prior filings. IceCure CEO Eyal Shamir began by highlighting the commercial momentum in the U.S., with total revenue increasing 26% year-over-year and U.S. sales up 83%, indicating the expansion of commercial activities and growing ProSense adoption. The company nearly doubled its U.S. commercial footprint, growing from 11 states to 21 states, by adding dedicated sales and marketing professionals in key regions and increasing physician engagement. Shamir also discussed the ChoICE post-marketing study, which has now established three clinical sites and enrolled the first patients at two U.S. centers. Additionally, the company secured regulatory approval in China and an exclusive distribution agreement in the Netherlands, expanding ProSense's international market presence.",
  "summary": "U.S. sales surged 83% while operating losses widened for the period.",
  "key_points": [
    "IceCure reported an 83% increase in U.S. sales, expanding to 21 states.",
    "Total revenue grew 26% year-over-year, driven by ProSense cryoablation system adoption.",
    "Company secured regulatory approval in China and distribution agreement in the Netherlands."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}